3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
82
Carcinoma, Non-Small-Cell Lung
72
Carcinoma, Renal Cell
42
Neoplasm Metastasis
31
Neoplasms
29
Squamous Cell Carcinoma of Head and Neck
26
Lung Neoplasms
25
Colorectal Neoplasms
23
Carcinoma, Hepatocellular
20
Hodgkin Disease
18
Small Cell Lung Carcinoma
17
Prostatic Neoplasms
14
Carcinoma, Transitional Cell
13
Head and Neck Neoplasms
12
Urinary Bladder Neoplasms
11
Pancreatic Neoplasms
11
Ovarian Neoplasms
11
Multiple Myeloma
11
Advanced Cancer
11
Triple Negative Breast Neoplasms
10
Lymphoma
10
Glioblastoma
10
Kidney Neoplasms
9
Breast Neoplasms
9
Recurrence
8
Lymphoma, Non-Hodgkin
8
Leukemia, Myeloid, Acute
8
Glioma
8
Stomach Neoplasms
7
Myelodysplastic Syndromes
7
Interventions
Temozolomide
7
Magnetic Resonance Spectroscopy
7
X-Rays
5
Phantoms, Imaging
5
Bevacizumab
5
Specimen Handling
4
Nuclear Medicine Department, Hospital
4
Carboplatin
3
Biopsy
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
Vemurafenib
2
Lapatinib
2
LY3023414
2
Everolimus
2
Etoposide
2
Erlotinib Hydrochloride
2
veliparib
1
pomalidomide
1
poly ICLC
1
picropodophyllin
1
marizomib
1
imetelstat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Ependymoma
×
Nivolumab
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts